Effect of finerenone and an SGLT2 inhibitor on the urine proteome: A CONFIDENCE analysis

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
 
Effect of finerenone and an SGLT2 inhibitor on the urine proteome: A CONFIDENCE analysis

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Mario
Berger
Mario Berger mario.berger@bayer.com Bayer AG, Pharmaceuticals R&D, Translational Sciences Wuppertal Germany *
Mark Andre De la Rambelje m.a.de.la.rambelje@umcg.nl University Medical Center Groningen, University of Groningen Department of Clinical Pharmacy and Pharmacology Groningen Netherlands -
Adam Skubala adam.skubala@bayer.com Bayer AG, Pharmaceuticals R&D, DS&AI Wuppertal Germany -
Sebastian Voss sebastian.voss.ext@bayer.com Evidenze Germany GmbH Biomarker Statistics & Data Science Essen Germany -
Aiden MacNamara aidan.macnamara@bayer.com Bayer AG, Pharmaceuticals R&D, Translational Sciences Wuppertal Germany -
Agnese Petrera agnese.petrera@helmholtz-munich.de German Research Centre for Environmental Health (GmbH),Helmholtz Zentrum Munich Metabolomics and Proteomics Core Neuherberg Germany -
Johanna Mielke johanna.mielke@bayer.com Bayer AG, Pharmaceuticals R&D, Translational Sciences Wuppertal Germany -
Rania Dayoub rania.dayoub@bayer.com Bayer AG, Pharmaceuticals Medical Affairs & Pharmacovigilance Berlin Germany -
Byung Wan Lee bwanlee@yuhs.ac Yonsei University College of Medicine Division of Endocrinology and Metabolism, Department of Internal Medicine Seoul South Korea -
Jonathan Barratt jonathan@jonathan-barratt-consulting.co.uk University of Leicester Department of Cardiovascular Sciences Leicester United Kingdom -
Rajiv Agarwal ragarwal@iu.edu Richard L. Roudebush VA Medical Center & Indiana University School of Medicine Division of Nephrology Indianapolis, IN United States -
David Cherney david.cherney@uhn.on.ca Toronto General Hospital University Health Network Toronto, ON Canada -
Hiddo J. L. Heerspink h.j.lambers.heerspink@med.umcg.nl University Medical Center Groningen, University of Groningen Department of Clinical Pharmacy and Pharmacology Groningen Netherlands - The George Institute for Global Health University of New South Wales Sydney Australia
Peter Rossing Peter.Rossing@RegionH.dk Steno Diabetes Center Copenhagen and University of Copenhagen Department of Clinical Medicine Copenhagen Denmark -
-